相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach
Guohong Han et al.
HEPATOLOGY (2020)
Role of locoregional therapies in the wake of systemic therapy
Daniel H. Palmer et al.
JOURNAL OF HEPATOLOGY (2020)
mRECIST for HCC: Performance and novel refinements
Josep M. Llovet et al.
JOURNAL OF HEPATOLOGY (2020)
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
Masatoshi Kudo et al.
LIVER CANCER (2020)
Six-and-twelve score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort
Xavier Adhoute et al.
WORLD JOURNAL OF HEPATOLOGY (2020)
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv238, 2018)
A. Vogel et al.
ANNALS OF ONCOLOGY (2019)
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
Josep M. Llovet et al.
JOURNAL OF HEPATOLOGY (2019)
Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study
Qiuhe Wang et al.
JOURNAL OF HEPATOLOGY (2019)
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach et al.
HEPATOLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
Jian Zhou et al.
LIVER CANCER (2018)
Performance status in patients with HCC: New kid on the block
Teh-Ia Huo et al.
JOURNAL OF HEPATOLOGY (2017)
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
Riccardo Lencioni et al.
JOURNAL OF HEPATOLOGY (2017)
Surrogate End Points and Their Validation in Oncology Clinical Trials
Fengmin Zhao
JOURNAL OF CLINICAL ONCOLOGY (2016)
Response assessment for HCC patients treated with repeated TACE: The optimal time-point is still an open issue
Wenjun Wang et al.
JOURNAL OF HEPATOLOGY (2015)
Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma
Beom Kyung Kim et al.
JOURNAL OF HEPATOLOGY (2015)
Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process
Xavier Adhoute et al.
JOURNAL OF HEPATOLOGY (2015)
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Joong-Won Park et al.
LIVER INTERNATIONAL (2015)
EASL- and mRECIST-Evaluated Responses to Combination Therapy of Sorafenib with Transarterial Chemoembolization Predict Survival in Patients with Hepatocellular Carcinoma
Lei Liu et al.
CLINICAL CANCER RESEARCH (2014)
mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)
H. J. Prajapati et al.
ANNALS OF ONCOLOGY (2013)
Intermediate hepatocellular carcinoma: current treatments and future perspectives
J-F Dufour et al.
ANNALS OF ONCOLOGY (2013)
Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation
Beom Kyung Kim et al.
EUROPEAN JOURNAL OF CANCER (2013)
The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma
Wolfgang Sieghart et al.
HEPATOLOGY (2013)
Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system
Chia-Yang Hsu et al.
HEPATOLOGY (2013)
Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma
D. Y. Kim et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Lack of Response after Initial Chemoembolization for Hepatocellular Carcinoma: Does It Predict Failure of Subsequent Treatment?
Christos Georgiades et al.
RADIOLOGY (2012)
Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization? A Validation Study of Old and New Models
Ju Hyun Shim et al.
RADIOLOGY (2012)
Radiographic Response to Locoregional Therapy in Hepatocellular Carcinoma Predicts Patient Survival Times
Khairuddin Memon et al.
GASTROENTEROLOGY (2011)
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic-pathologic correlation
Ahsun Riaz et al.
JOURNAL OF HEPATOLOGY (2011)
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation
Roopinder Gillmore et al.
JOURNAL OF HEPATOLOGY (2011)
Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma
Ahsun Riaz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy
Stephen L. Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Induction of complete tumor necrosis may reduce intrahepatic metastasis and prolong survival in patients with hepatocellular carcinoma undergoing locoregional therapy: a prospective study
TI Huo et al.
ANNALS OF ONCOLOGY (2004)
分享论文
